Skip to main content

Jolla Value Stock - Dividend - Research Selection

La Jolla Pharmaceutical

ISIN: US5034596040, WKN: A1XB6B

Market price date: 20.01.2022
Market price: 4,55 USD

La Jolla Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 17-03-2021
Cash flow
Net operating cash flow -37.640.000
Capital Expenditures -1
Free cash flow -37.640.000
Balance sheet
Total Equity -88.087.000
Liabilities & Shareholders equity 72.243.000
Income statement
Net income -39.420.000
Eps (diluted) -1,440
Diluted shares outstanding 27.000.000
Net sales/revenue 33.420.000

Fundamental ratios calculated on: 20-01-2022

Key figures 20-01-2022
Cash flow
P/C -3,26
P/FC -3,26
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization122.850.000,00 USD
CountryUnited States
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-01-14,1.000000/50.000000; 2012-02-17,1.000000/100.000000; 2011-04-15,1.000000/100.000000; 2005-12-22,1.000000/5.000000

Description of the company

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media

Microsoft takes big $68.7 billion swing on video game company Activision Blizzard while legacy media stays on sidelines

Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that

President Biden urged companies to voluntarily impose Covid vaccination rules on workers after the Supreme Court blocked a government order to do that.

Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda

Two of Sen. Kyrsten Sinema's former aides have become key aides for corporate giants looking to impact President Joe Biden's agenda.

Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda

Former aides to Sen. Joe Manchin who are now lobbyists are scoring big clients as their ex-boss battles President Biden's agenda

Pixar's 'Turning Red' to skip theaters, head straight to Disney+ in March

"Turning Red" is the third Pixar film to transition to Disney's streaming platform during the pandemic.

Microsoft, NVIDIA, and Dick's are some of today's stock picks for investors: Pro Market Movers Jan. 6

Jim Cramer, Dan Ives of Wedbush Securities, Gene Munster of Loup, Aaron Kessler of Raymond James, Dan Niles of Satori Fund, Darrin Peller of Wolfe Research, Josh Brown of Ritholtz Wealth Management, Brenda Vingiello of Sand Hill Global Advisors, Sarat Sethi of DCLA, and Steve Weiss of Short Hills Capital explain why they are buying, selling, or holding specific stocks and ETFs

Watch CNBC's full interview with Sarat Sethi on his top stock picks for 2022

Sarat Sethi, DCLA managing partner and portfolio manager, joins the 'Halftime Report' to discuss his top stock picks for 2022, which include Uber, Morgan Stanley, and Comcast.

With just $36.6 million in ticket sales, ‘West Side Story’ is officially a box office bomb

"West Side Story" is a box office bomb, having only generated around $36 million in ticket sales on a $100 million production budget.

'Spider-Man: No Way Home' provides hope for the 2022 box office, but there are still hurdles ahead

"Spider-Man: No Way Home" proves that audiences are ready to return to movie theaters, but the industry still faces major obstacles.